N-(4-硝基苄基)乙胺 | 17847-35-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-硝基苄基)乙胺
• 英文名称: N-(4-nitrobenzyl)ethanamine
• 英文别名: N-[(4-nitrophenyl)methyl]ethanamine
• CAS: 17847-35-7
• 化学式: C₉H₁₂N₂O₂
• mdl: MFCD07407318
• 分子量: 180.206
• InChiKey: CRBKFFVPLITHLR-UHFFFAOYSA-N

物化性质

• 沸点：
  292.1±15.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(4-硝基苄基)乙胺 生成 2-ethyl-2H-indazole
  参考文献：
  名称：

  2-Substituted indazoles from electrogenerated ortho-nitrosobenzylamines

  摘要：

  An electrochemical methodology for an efficient access to ortho-nitrosobenzylamines has been developed. These products cyclize intramolecularly producing the desired 2-substituted indazoles in high yields. The electrochemical procedure overcomes limitations of previous chemical methods. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(98)00058-1
• 作为产物：
  描述：

  N-乙基苄胺 在 盐酸 、 硝酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 6.3h， 生成 N-(4-硝基苄基)乙胺
  参考文献：
  名称：

  一种制备4-氨基-N-烷基苄胺的方法

  摘要：

  本发明属于有机中间体的制备方法，具体涉及一种制备4‑氨基‑N‑烷基苄胺的方法。以N‑烷基苄胺为原料经乙酰化、定位硝化、脱保护基、在多组份骨架Ni‑Fe‑Cu催化剂存在下进行加氢还原，总收率90％以上。本发明提供的合成4‑氨基‑N‑烷基苄胺的方法，具有工艺简单，操作条件温和、污染小，反应所用催化剂活性和选择性高，催化加氢选择性99.9％以上，收率99％以上，催化剂可以反复套用，与传统工艺相比，能有效降低生产成本。

  公开号：

  CN105001096B

文献信息

• Zirconium-hydride-catalyzed site-selective hydroboration of amides for the synthesis of amines: Mechanism, scope, and application
  作者：Bo Han、Jiong Zhang、Haijun Jiao、Lipeng Wu

  DOI：10.1016/s1872-2067(21)63853-6

  日期：2021.11

  diverse amines. Various readily reducible functional groups, such as esters, alkynes, and alkenes, were well tolerated. Furthermore, the methodology was extended to the synthesis of bio- and drug-derived amines. Detailed mechanistic studies revealed a reaction pathway entailing aldehyde and amido complex formation via an unusual C–N bond cleavage-reformation process, followed by C–O bond cleavage.

  开发用于选择性合成胺的温和高效的催化方法是一个长期的研究目标。在这方面，催化脱氧酰胺还原已被证明是有前途但具有挑战性的，因为这种方法需要选择性的 C-O 键裂解。在此，我们报告了伯、仲和叔酰胺在室温下由地球丰富的金属催化剂 Zr-H 催化的选择性硼氢化反应，以获取不同的胺。各种易于还原的官能团，如酯、炔烃和烯烃，都具有良好的耐受性。此外，该方法还扩展到生物和药物衍生胺的合成。详细的机理研究揭示了一个反应途径，通过一个不寻常的 C-N 键断裂-重整过程形成醛和酰胺复合物，然后是 C-O 键断裂。
• [EN] QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER<br/>[FR] DERIVES DE QUINAZOLINE A UTILISER CONTRE LE CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2006040526A1

  公开（公告）日：2006-04-20

  The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

  本发明涉及式(I)喹唑啉衍生物或其药物可接受的盐、溶剂化物或前药，其中p、R1、q、R2、R3、R4、R5、环A、X1、R6、r和R7各自具有说明书中定义的任何含义；其制备方法、含有它们的药物组合物以及它们在制造用于治疗细胞增殖障碍或治疗与血管生成和/或血管通透性相关的疾病状态的药物中的应用。
• [EN] COMPOUNDS FOR THE MODULATION OF CYCLOPHILINS FUNCTION<br/>[FR] COMPOSÉS POUR LA MODULATION DE LA FONCTION DES CYCLOPHILINES
  申请人：UNIV COURT UNIV OF EDINBURGH

  公开号：WO2020043831A1

  公开（公告）日：2020-03-05

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compounds in the treatment of various disorders. Formula (I), wherein: R1 and R2 are each independently is selected from the group consisting of -R, -haloalkyl, -hydroxyalkyl, -OR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, and - N(R)2; wherein R2 could also be a sulphide; each R is independently hydrogen, C 1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms selected from nitrogen, oxygen, or sulphur; R3 is Formual (Ia) selected from the group consisting of -OEt, and wherein R5 and R6 are independently selected from the group consisting of H, halide, methoxy, thiomethyl, morpholine and trifluoromethyl;R4 is selected from the group consisting of C1-6-alkyl-, and R4.1-CH2- wherein, R4.1 is C3-6-cycloalkyl-, a 5-6 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, sulphur; optionally substituted with one R4.1.1 wherein, R4.1.1 is selected from -H, C1-4-alkyl, optionally substituted with one substituent selected from H2N(O)C- or EtO(O)C-;X is carbon or nitrogen; A is selected from the group consisting of 6 membered unsaturated ring, with 1-3 nitrogen atoms, which is optionally substituted by -NH2,and Formula (Ib), wherein ring B is a fused 5-10 membered saturated or partially unsaturated heterocyclic mono- bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen or sulphur, which is optionally substituted by -OH; and m is 1 or 2; and n is 1 or 2.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其作为环肽酶的抑制剂和环肽酶样蛋白的调节剂。该发明还涉及所述化合物在治疗各种疾病中的用途。式(I)中：R1和R2各自独立地选自由-R、-卤代烷基、-羟基烷基、-OR、-C(O)R、-CO2R、-C(O)N(R)2、-NRC(O)R和-N(R)2等组成的群；其中R2也可以是硫化物；每个R独立地是氢、C1-6脂肪基、C3-10芳基、一个3-8成员饱和或部分不饱和的碳环、一个具有1-4个异原子（从氮、氧、硫中独立选择）的3-7成员杂环、或一个具有1-4个异原子（从氮、氧、硫中选择）的5-6成员单环杂芳基；R3是式(Ia)中选自-OEt的群，其中R5和R6各自独立地选自H、卤素、甲氧基、硫甲基、吗啉和三氟甲基的群；R4选自C1-6-烷基-和R4.1-CH2-，其中，R4.1是C3-6环烷基-、一个具有1-4个异原子（从氮、氧、硫中独立选择）的5-6成员杂环，可选地用一个R4.1.1取代，其中R4.1.1选自-H、C1-4-烷基，可选地用一个取代基（从H2N(O)C-或EtO(O)C-中选择）取代；X是碳或氮；A选自具有1-3个氮原子的6成员不饱和环，可选地用-NH2取代；和式(Ib)，其中环B是一个融合的5-10成员饱和或部分不饱和的杂环单双环，具有1-3个从氮、氧或硫中选择的异原子，可选地用-OH取代；m为1或2；n为1或2。
• Substituted indolines which inhibit receptor tyrosine kinases
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06762180B1

  公开（公告）日：2004-07-13

  Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.

  公式为的吲哚酮对受体酪氨酸激酶和细胞周期蛋白/CDK复合物，以及内皮细胞和各种肿瘤细胞的增殖具有抑制作用。示例包括： (a) 3-Z-[1-(4-(哌啶-1-基甲基)-苯胺基)-1-苯基亚甲基]-6-乙氧羰基-2-吲哚酮， (b) 3-Z-(1-(4-(哌啶-1-基甲基)-苯胺基)-1-苯基亚甲基)-6-氨基甲酰基-2-吲哚酮，以及 (c) 3-Z-[1-(4-(哌啶-1-基甲基)-苯胺基)-1-苯基亚甲基]-6-甲氧羰基-2-吲哚酮。
• Substituted indolinones with kinase inhibitory activity
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06319918B1

  公开（公告）日：2001-11-20

  Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone and 3-Z-[1-(4-(2,3,4,5-Tetrahydro-benzo(d)azepin-3-yl-methyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone.

  通用公式的替代吲哚酮对各种激酶和细胞周期素/CDK复合物以及各种肿瘤细胞的增殖具有影响。示例化合物包括：3-Z-[1-(4-(N-苄基-N-甲基氨甲基)-苯胺基)-1-甲基亚甲基]-5-氨基-2-吲哚酮和3-Z-[1-(4-(2,3,4,5-四氢苯并(d)氮杂环己-3-基甲基)-苯胺基)-1-甲基亚甲基]-5-氨基-2-吲哚酮。